Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Meta Expands AI Training With Employee Activity Tracking Tools 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
OXFORD, United Kingdom, March 15, 2017 -- Summit Therapeutics plc (NASDAQ:SMMT)(AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the Oppenheimer 27th Annual Healthcare Conference, 22 March 2017 at 2:10pm EDT in New York City.
A live audio webcast of the presentation will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit Therapeutics Glyn Edwards / Richard Pye (UK office) Erik Ostrowski / Michelle Avery (US office) | Tel: +44 (0)1235 443 951 +1 617 225 4455 |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson | Tel: +44 (0)20 7213 0880 |
| N+1 Singer (Broker) Aubrey Powell / Jen Boorer | Tel: +44 (0)20 7496 3000 |
| MacDougall Biomedical Communications (US media contact) Chris Erdman / Karen Sharma | Tel: +1 781 235 3060 [email protected] [email protected] |
| Consilium Strategic Communications (Financial public relations, UK) Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey Neville | Tel: +44 (0)20 3709 5700 [email protected] |
-END-
